Abstract A225: Identification of a Promising PI3K Inhibitor for the Treatment of Multiple Myeloma Through Structural Optimization.
Kunkun Han,Xin Xu,Guodong Chen,Yuanying Zeng,Jingyu Zhu,Xiaolin Du,Zubin Zhang,Biyin Cao,Zhaopeng Liu,Xinliang Mao
DOI: https://doi.org/10.1158/1535-7163.targ-13-a225
2013-01-01
Molecular Cancer Therapeutics
Abstract:Multiple myeloma (MM) is an incurable malignancy of plasma cells, which is associated with the overactivated phosphatidylinositol 3-kinases (PI3Ks)/AKT signaling pathway. Stimulated by interleukin 6 and or insulin-like growth factor 1, PI3K/AKT plays a key role in MM survival and chemoresistance, while genetic knockdown of these PI3-kinases by small interfering RNA (siRNA) leads to MM cell apoptosis and decreased proliferation. Therefore, PI3K is granted as a promising therapeutic target for MM. We previously identified the small molecule compound S14161 an inhibitor of pan-Class I PI3K isoforms by a high throughput screening strategy (Mao et al., 2011). S14161 displayed potent preclinical activity against MM and leukemia in vitro and in vivo. In the present study, we synthesized a panel of S14161 analogs based on the structure-activity relationship, of which BENC-511 was demonstrated to be more potent than S14161 in suppressing PI3K activity and inducing MM cell death. BENC-511 was derived from S14161 by removing 4-fluorophenyl group at the 2-position of the chromene core. Different from S14161, BENC-511 presented as a specific inhibitor for PI3K α and δ, but had no inhibitory effects on PI3K β, γ, AKT, or mTOR in the cell-free enzymatic assays. BENC-511 inhibited phosphorylation of AKT and its downstream signals mTOR, P70S6K, and 4E-BP-1 at low micromolar concentrations. Consistent with its effects on PI3K activity and cancer cell proliferation, BENC-511 induced MM cell apoptosis. Notably, addition of insulin-like growth factor 1 and interleukin-6, two important triggers for PI3K activation in MM cells, partly blocked BENC-511-induced MM cell death. BENC-511 also showed potent anti-myeloma activity in vivo. Oral administration of BENC-511 decreased tumor growth up to 80% within 3 weeks in two independent MM xenograft models, but presented minimal toxicity. Suppression of BENC-511 on MM tumor growth was associated with decreased PI3K/AKT activity and increased cell apoptosis. Because of its robust potential and low toxicity (LD50 oral >1.5 g/kg), BENC-511 could be developed as a promising agent for the treatment of multiple myeloma by targeting the PI3K/AKT signaling pathway. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):A225. Citation Format: Kunkun Han, Xin Xu, Guodong Chen, Yuanying Zeng, Jingyu Zhu, Xiaolin Du, Zubin Zhang, Biyin Cao, Zhaopeng Liu, Xinliang Mao. Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through structural optimization. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A225.